Anti-Mouse/Human IL-5 [Clone TRFK5] — Purified No Carrier Protein

Partially-purified T cell clone supernatant

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Additional reported applications (for the relevant formats) include:
Neutralization
Flow Cytometry
Western Blotting
IHC-FFPE
IHC-FF

Clone TRFK5 recognizes mouse/human IL-5.

IL-5 is a 26 kD TH2 cytokine and a homodimeric glycoprotein that is part of the hematopoietic family. IL-5 stimulates B cell growth as well as increases Ig secretion. It is the main factor that promotes the terminal differentiation of eosinophil progenitors and enhances the effector capacity of mature eosinophils. IL-5 is a major regulator of eosinophil accumulation in tissues. In fact, in Hodgkin lymphoma, the characteristically observed eosinophilia is suspected to result from an increased production of IL-5. IL-5 may also be the cause of several allergic diseases including asthma, where it is thought that eosinophils have a significant role in the disease pathology. There are several mAbs currently in use that target IL-5 for the treatment of severe eosinophilic asthma.